Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2015 · 10-Q
Revenue$28.74M$28.74M+216.5% vs Q1 2014 Net Income$738.00K$738.00KN/M vs Q1 2014 EPS Diluted$0.02$0.02N/M vs Q1 2014 Operating Income$4,034,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$314,000N/M Margins · derivedOperating margin14.0%+161.8 pt vs Q1 2014
Net margin2.6%+173.7 pt vs Q1 2014
ended Mar 31, 2015 · filed May 6, 2015 · 36 d after period end